Latest News and Press Releases

Spur Therapeutics Announces Development Candidate in Parkinson’s Disease Gene Therapy Program

Spur Therapeutics to Participate in Upcoming Investor Conferences

Spur Therapeutics to Participate in B. Riley Securities’ Next-Gen Tissue Delivery Modalities Virtual Summit

Spur Therapeutics Publishes Preclinical Proof-of-Concept Data for SBT101, its Gene Therapy Candidate in Adrenomyeloneuropathy (AMN)

Spur Therapeutics Showcases Positive New Data from Phase 1/2 GALILEO-1 Trial of FLT201, Its Novel Gene Therapy Candidate for Gaucher Disease

LONDON, Oct. 03, 2024 (GLOBE NEWSWIRE) -- Spur Therapeutics, formerly Freeline Therapeutics, today announced that it will present updated clinical data from its GALILEO-1 first-in-human clinical...

Spur Therapeutics to Participate in Chardan’s 8th Annual Genetic Medicines Conference

Single infusion of FLT201 at low dose of 4.5e11 vg/kg demonstrates compelling safety and benefit Expect to initiate Phase 3 registrational trial in 2025 LONDON, July 08, 2024 (GLOBE NEWSWIRE) --...

Rationally engineered GCase85 enzyme reduces α-Synuclein accumulation, which plays a key role in the development and progression of Parkinson’s, in neuronal cells more effectively than wildtype GCase ...

Spur Therapeutics to Participate in the H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference